Floatz logo

Mesna

Demyelinating Diseases

Indapta Therapeutics, INC.Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Demyelinating Diseases cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Amsterdam UMC, location VUmc
Phase 3B
CLEMASTIN
University of California, San Francisco
Phase 1/2CCC
Cyclophosphamide
Indapta Therapeutics, INC.
Phase 1CC
Idp-023
Indapta Therapeutics, INC.
Phase 1CC
Fludarabine
Indapta Therapeutics, INC.
Phase 1CC
Ocrevus
Indapta Therapeutics, INC.
Phase 1CC

Same molecule, other indications

Mesna is also rated in:

Hodgkin's LymphomaDormant
BB
Indicative ·
69 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
BB
Indicative ·
69 / 100
View asset →
NK/T-cell LymphomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →